Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Nasopharyngeal Carcinoma 3 Uterine Cervical Neoplasms 1 Solid Tumors 1 Sarcoma 1 Nasopharyngeal Neoplasms 1 Melanoma 1 Esophageal Squamous Cell Carcinoma 1 Colorectal Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Nivolumab 25 Specimen Handling 19 cabozantinib 15 pembrolizumab 13 Magnetic Resonance Spectroscopy 13 Ipilimumab 13 belzutifan 12 lenvatinib 7 CTLA-4 Antigen 7 Biopsy 7 Axitinib 7 atezolizumab 4 Sunitinib 4 tivozanib 3 Surveys and Questionnaires 3 Immunoglobulin G 3 Everolimus 3 Disulfides 3 zimberelimab 2 relatlimab 2 pazopanib 2 palbociclib 2 aldesleukin 2 X-Rays 2 Watchful Waiting 2 Standard of Care 2 Radiosurgery 2 Practice Guidelines as Topic 2 Nephrectomy 2 Bevacizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Renal Cell × spartalizumab × 30 days × Clear all

NCT07571551 2026-05-11

TRIPLE-PATH

Jinling Hospital, China

Phase 2 Recruiting

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡